Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sai Sahana Sundararaman, Yvonne Döring, Emiel P. C. van der Vorst
Biomedicines (2021) Vol. 9, Iss. 7, pp. 793-793
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Xuhui Bao, Yongjun Liang, Hanman Chang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
Emily Punch, Justus Klein, Patrick Diaba‐Nuhoho, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 3
Open Access | Times Cited: 58
Cholesterol and COVID-19—therapeutic opportunities at the host/virus interface during cell entry
Thomas Grewal, Mai Khanh Linh Nguyen, Christa Buechler
Life Science Alliance (2024) Vol. 7, Iss. 5, pp. e202302453-e202302453
Open Access | Times Cited: 9
Research Progress and Clinical Translation Potential of Coronary Atherosclerosis Diagnostic Markers from a Genomic Perspective
Hanxiang Liu, Yuchen Zhang, Yueyan Zhao, et al.
Genes (2025) Vol. 16, Iss. 1, pp. 98-98
Open Access | Times Cited: 1
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Douglas P. Loesch, Manik Garg, Dorota Matelska, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis
Ibrahim Oluwatobi Kehinde, Oluwole B. Akawa, Adeniyi T. Adewumi, et al.
Journal of Cellular Biochemistry (2024) Vol. 125, Iss. 7
Closed Access | Times Cited: 6
Atherosclerosis: an overview of mouse models and a detailed methodology to quantify lesions in the aortic root
Jamie I. van der Vaart, Robin van Eenige, Patrick C.N. Rensen, et al.
Vascular Biology (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 6
Fibroblasts’ secretome from calcified and non-calcified dermis in Pseudoxanthoma elasticum differently contributes to elastin calcification
Francesco Demetrio Lofaro, Sónia Costa, Maria Luisa Simone, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 5
Advancing personalized medicine with 3D printed combination drug therapies: A comprehensive review of application in various conditions
Hooman Hatami, Mohammad M. Mojahedian, Prashant Kesharwani, et al.
European Polymer Journal (2024) Vol. 215, pp. 113245-113245
Closed Access | Times Cited: 5
Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
Lung‐An Hsu, Ming‐Sheng Teng, Semon Wu, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10418-10418
Open Access | Times Cited: 18
PCSK9 in Vascular Aging and Age-Related Diseases
Dong Tan, Xin Yang, Jing Yang, et al.
Aging and Disease (2025)
Open Access
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
Assunta Di Costanzo, Ciro Indolfi, Sabato Sorrentino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11739-11739
Open Access | Times Cited: 9
Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels
Patricia Mester, Pablo Amend, Stephan Schmid, et al.
Infectious Disease Reports (2024) Vol. 16, Iss. 4, pp. 593-607
Open Access | Times Cited: 3
Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
Thomas Grewal, Christa Buechler
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1070-1070
Open Access | Times Cited: 14
Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Marianna Puccini, Ulf Landmesser, Ursula Rauch
Metabolites (2022) Vol. 12, Iss. 3, pp. 226-226
Open Access | Times Cited: 14
Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
Giulio Preta
Cells (2023) Vol. 12, Iss. 20, pp. 2466-2466
Open Access | Times Cited: 7
Carotenoids Interaction with PCSK9: Exploring Novel Cholesterol-Lowering Strategies
Alessandro Medoro, Giovanni Scapagnini, Simone Brogi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1597-1597
Open Access | Times Cited: 2
The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment
Gabriella Testa, Serena Giannelli, Erica Staurenghi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13637-13637
Open Access | Times Cited: 2
Dynamics of the personalities of PCSK9 on missense variants (rs505151 and rs562556) from elderly cohort studies in Brazil
Vitor Galvão Lopes, Victor Fernandes de Oliveira, Lívia Mendonça Munhoz Dati, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 24, pp. 15625-15633
Open Access | Times Cited: 6
Functional Crosstalk between PCSK9 Internalization and Pro-Inflammatory Activation in Human Macrophages: Role of Reactive Oxygen Species Release
Rafael I. Jaén, Adrián Povo‐Retana, César Rosales-Mendoza, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9114-9114
Open Access | Times Cited: 10
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
Anastasia V. Poznyak, Vasily N. Sukhorukov, Ilya I. Eremin, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 503-503
Open Access | Times Cited: 5
Tissue and Serum Biomarkers in Degenerative Aortic Stenosis-Insights into Pathogenesis, Prevention and Therapy
Alkistis Kapelouzou, Styliani Geronikolou, Irene Lidoriki, et al.
Biology (2023) Vol. 12, Iss. 3, pp. 347-347
Open Access | Times Cited: 5
Research on Hepatocyte Regulation of PCSK9-LDLR and Its Related Drug Targets
Su-su Liu, Tong Yu, Yan-fang Qiao, et al.
Chinese Journal of Integrative Medicine (2023) Vol. 30, Iss. 7, pp. 664-672
Closed Access | Times Cited: 5
Anti-PCSK9 Treatment Attenuates Liver Fibrosis via Inhibiting Hypoxia-Induced Autophagy in Hepatocytes
Liuxin Ning, Yanting Zou, Shuyu Li, et al.
Inflammation (2023) Vol. 46, Iss. 6, pp. 2102-2119
Open Access | Times Cited: 5
The Anti-Thrombotic Effects of PCSK9 Inhibitors
Martin Jozef Péč, J Benko, Jakub Jurica, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1197-1197
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top